Pegylated synthetic human C-peptide

CBX129801 is a pegylated form of synthetic human C-peptide developed to extend the half-life of native C-peptide in circulation. It was investigated as a replacement therapy for patients with type 1 diabetes, particularly targeting diabetic peripheral neuropathy, a common complication in this population. The drug is administered subcutaneously and aims to restore physiological levels of circulating C-peptide. Mechanistically, it acts as an adenosine triphosphatase stimulant, nerve growth factor stimulant, and nitric oxide synthase stimulant—mechanisms believed to support nerve function and repair. Clinical development reached phase 2 trials for type 1 diabetes and diabetic neuropathies but has since been discontinued[2][3][4][5][6].

Brand names

Ersatta

Other names

PEGYLATED HUMAN C-PEPTIDEPEGYLATED SYNTHETIC HUMAN C-PEPTIDEPEGylated C-peptideC-peptide long-acting